Precision Solutions

• 
  Bispecific Antibody Custom Development — 15+ Formats, >90% Success Rate

  AtaGenix provides end-to-end bispecific antibody custom development supporting 15+ formats (BiTE, IgG-like, Fab-based, nanobody-based, multispecific). >90% project success rate using proprietary HEK293 and XtenCHO™ expression platforms. Full workflow from gene synthesis and vector construction to expression, purification, and QC (SDS-PAGE, SEC-HPLC, ELISA) in 5–6 weeks. Case studies include anti-EBV gH/gL and anti-GPC3×CD3E bispecific antibodies.